New Antibody Formats

<p>. Current innovative engineered antibodies<br>Jose Yelamos<br>2. Opportunities and challenges of bi-specific antibodies<br>Aina Segués, Shuyu Huang, Alice Sijts, Pedro Berraondo and Dietmar M. Zaiss<br>3. Applications of trimerbodies in cancer immunotherapy<br>Marta Compte, Laura Sanz and Luis Álvarez-Vallina<br>4. Anticalin®-based therapeutics: Expanding new frontiers in drug development<br>Aizea Morales-Kastresana, Martin Siegemund, Stefan Haak, Janet Peper-Gabriel, Vanessa Neiens and Christine Rothe<br>5. Overcoming the limitations of cytokines to improve cancer therapy<br>Claudia Augusta Di Trani, Assunta Cirella, Leire Arrizabalaga, Myriam Fernandez-Sendin, Angela Bella, Fernando Aranda, Ignacio Melero and Pedro Berraondo<br>6. Emerging applications of nanobodies in cancer therapy<br>Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W.M. De Groof, Yannick De Vlaeminck, Ahmet Krasniqi, Kim De Veirman, Cleo Goyvaerts, Matthias D’Huyvetter, Sophie Hernot, Nick Devoogdt and Karine Breckpot</p>